MedTrace Logo

Developing Breast (Cancer) Organoids

NCT05317221 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-05-12

No results posted yet for this study

Summary

Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening.

This now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes.

Goal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are:

1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour?
2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions?
3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients?
4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?

Conditions

Interventions

OTHER

Not an extra intervention, tissue taken in routine practice will be used.

No extra intervention: using tumour tissue taken during surgery in standard of care.

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Maastricht University

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Marc Vooijs, PhD · Maastricht University

  • Marjolein Smidt, MD, PhD · Maastricht University Medical Center

  • Loes Kooreman, MD · Maastricht University Hospital (MUMC+)

  • Maaike De Boer, MD, PhD · Maastricht University Hospital (MUMC+)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2028-04-01
Completion
2028-05-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05317221 on ClinicalTrials.gov